Loading…
Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery
Curing malignant carcinomas is a grand ambition in the development of human health. Over the past decades, targeted therapies have become one of the most successful ways of achieving this. Of these approaches, small molecule inhibitors and monoclonal antibodies are two major methods, however several...
Saved in:
Published in: | RSC advances 2019-05, Vol.9 (3), p.16967-16976 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c520t-2c01dd60f46c019bc9d295b2dbe868dab55e1505816dde67a5e42e7af08ea2f93 |
---|---|
cites | cdi_FETCH-LOGICAL-c520t-2c01dd60f46c019bc9d295b2dbe868dab55e1505816dde67a5e42e7af08ea2f93 |
container_end_page | 16976 |
container_issue | 3 |
container_start_page | 16967 |
container_title | RSC advances |
container_volume | 9 |
creator | Pei, Haixiang Peng, Yangrui Zhao, Qiuhua Chen, Yihua |
description | Curing malignant carcinomas is a grand ambition in the development of human health. Over the past decades, targeted therapies have become one of the most successful ways of achieving this. Of these approaches, small molecule inhibitors and monoclonal antibodies are two major methods, however several barriers to their development and clinical use still exist. The use of proteolysis-targeting chimeras (PROTACs) is a new technology through utilizing a intracellular ubiquitin-proteasome system to induce targeted protein degradation, is receiving much attention in the field of targeted therapies. Hetero-bifunctional PROTACs have the potential to eliminate the "undruggable" proteome that comprises about 85% of human proteins, which indicates their great prospects in therapeutic fields. However, there are some hurdles preventing current PROTACs moving from bench to clinic, such as delivery and bioavailability. This review provides an overview of the development of PROTAC technology and will briefly summarize the future possible directions of this approach.
An overview of the latest developments in PROTAC technology and the possible directions of this approach is presented. |
doi_str_mv | 10.1039/c9ra03423d |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1039_C9RA03423D</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2241344122</sourcerecordid><originalsourceid>FETCH-LOGICAL-c520t-2c01dd60f46c019bc9d295b2dbe868dab55e1505816dde67a5e42e7af08ea2f93</originalsourceid><addsrcrecordid>eNp9kd1LHDEUxUNpqaK-9L2S0pcirOZjkp34UFhWbQVB8eM5ZJI7syOZyZrMCPvfN7p2a33wvtwL58fhHg5CXyg5pISrI6uiIbxg3H1A24wUcsKIVB9f3VtoL6V7kkcKyiT9jLa4EFSVU7GN7m464z3uggc7esBX15e3s3k6xqbH0EFs2r7BA9hFH3xoVrgOEQ8mNjCAw8MColmucNtjF8cGuzbZ8AhxtYs-1cYn2HvZO-ju7PR2_ntycfnrfD67mFjByDBhllDnJKkLmS9VWeWYEhVzFZSydKYSAqggoqTSOZBTI6BgMDU1KcGwWvEd9HPtuxyrDpyFfojG62VsOxNXOphW_6_07UI34VErIgupeDb48WIQw8MIadBdzgDemx7CmDSTkpKSKc4y-v0Neh_G2Od4mrGC8qKg7Ik6WFM2hpQi1JtnKNFPhem5up49F3aS4f3X72_Qv_Vk4OsaiMlu1H-NZ_3be7peupr_AfSZpls</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2241344122</pqid></control><display><type>article</type><title>Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery</title><source>PubMed Central</source><creator>Pei, Haixiang ; Peng, Yangrui ; Zhao, Qiuhua ; Chen, Yihua</creator><creatorcontrib>Pei, Haixiang ; Peng, Yangrui ; Zhao, Qiuhua ; Chen, Yihua</creatorcontrib><description>Curing malignant carcinomas is a grand ambition in the development of human health. Over the past decades, targeted therapies have become one of the most successful ways of achieving this. Of these approaches, small molecule inhibitors and monoclonal antibodies are two major methods, however several barriers to their development and clinical use still exist. The use of proteolysis-targeting chimeras (PROTACs) is a new technology through utilizing a intracellular ubiquitin-proteasome system to induce targeted protein degradation, is receiving much attention in the field of targeted therapies. Hetero-bifunctional PROTACs have the potential to eliminate the "undruggable" proteome that comprises about 85% of human proteins, which indicates their great prospects in therapeutic fields. However, there are some hurdles preventing current PROTACs moving from bench to clinic, such as delivery and bioavailability. This review provides an overview of the development of PROTAC technology and will briefly summarize the future possible directions of this approach.
An overview of the latest developments in PROTAC technology and the possible directions of this approach is presented.</description><identifier>ISSN: 2046-2069</identifier><identifier>EISSN: 2046-2069</identifier><identifier>DOI: 10.1039/c9ra03423d</identifier><identifier>PMID: 35519875</identifier><language>eng</language><publisher>England: Royal Society of Chemistry</publisher><subject>Bioavailability ; Chemistry ; Monoclonal antibodies ; New technology ; Proteins</subject><ispartof>RSC advances, 2019-05, Vol.9 (3), p.16967-16976</ispartof><rights>This journal is © The Royal Society of Chemistry.</rights><rights>Copyright Royal Society of Chemistry 2019</rights><rights>This journal is © The Royal Society of Chemistry 2019 The Royal Society of Chemistry</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c520t-2c01dd60f46c019bc9d295b2dbe868dab55e1505816dde67a5e42e7af08ea2f93</citedby><cites>FETCH-LOGICAL-c520t-2c01dd60f46c019bc9d295b2dbe868dab55e1505816dde67a5e42e7af08ea2f93</cites><orcidid>0000-0003-4031-447X ; 0000-0003-1733-7980</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064693/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064693/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35519875$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pei, Haixiang</creatorcontrib><creatorcontrib>Peng, Yangrui</creatorcontrib><creatorcontrib>Zhao, Qiuhua</creatorcontrib><creatorcontrib>Chen, Yihua</creatorcontrib><title>Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery</title><title>RSC advances</title><addtitle>RSC Adv</addtitle><description>Curing malignant carcinomas is a grand ambition in the development of human health. Over the past decades, targeted therapies have become one of the most successful ways of achieving this. Of these approaches, small molecule inhibitors and monoclonal antibodies are two major methods, however several barriers to their development and clinical use still exist. The use of proteolysis-targeting chimeras (PROTACs) is a new technology through utilizing a intracellular ubiquitin-proteasome system to induce targeted protein degradation, is receiving much attention in the field of targeted therapies. Hetero-bifunctional PROTACs have the potential to eliminate the "undruggable" proteome that comprises about 85% of human proteins, which indicates their great prospects in therapeutic fields. However, there are some hurdles preventing current PROTACs moving from bench to clinic, such as delivery and bioavailability. This review provides an overview of the development of PROTAC technology and will briefly summarize the future possible directions of this approach.
An overview of the latest developments in PROTAC technology and the possible directions of this approach is presented.</description><subject>Bioavailability</subject><subject>Chemistry</subject><subject>Monoclonal antibodies</subject><subject>New technology</subject><subject>Proteins</subject><issn>2046-2069</issn><issn>2046-2069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kd1LHDEUxUNpqaK-9L2S0pcirOZjkp34UFhWbQVB8eM5ZJI7syOZyZrMCPvfN7p2a33wvtwL58fhHg5CXyg5pISrI6uiIbxg3H1A24wUcsKIVB9f3VtoL6V7kkcKyiT9jLa4EFSVU7GN7m464z3uggc7esBX15e3s3k6xqbH0EFs2r7BA9hFH3xoVrgOEQ8mNjCAw8MColmucNtjF8cGuzbZ8AhxtYs-1cYn2HvZO-ju7PR2_ntycfnrfD67mFjByDBhllDnJKkLmS9VWeWYEhVzFZSydKYSAqggoqTSOZBTI6BgMDU1KcGwWvEd9HPtuxyrDpyFfojG62VsOxNXOphW_6_07UI34VErIgupeDb48WIQw8MIadBdzgDemx7CmDSTkpKSKc4y-v0Neh_G2Od4mrGC8qKg7Ik6WFM2hpQi1JtnKNFPhem5up49F3aS4f3X72_Qv_Vk4OsaiMlu1H-NZ_3be7peupr_AfSZpls</recordid><startdate>20190530</startdate><enddate>20190530</enddate><creator>Pei, Haixiang</creator><creator>Peng, Yangrui</creator><creator>Zhao, Qiuhua</creator><creator>Chen, Yihua</creator><general>Royal Society of Chemistry</general><general>The Royal Society of Chemistry</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SR</scope><scope>8BQ</scope><scope>8FD</scope><scope>JG9</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4031-447X</orcidid><orcidid>https://orcid.org/0000-0003-1733-7980</orcidid></search><sort><creationdate>20190530</creationdate><title>Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery</title><author>Pei, Haixiang ; Peng, Yangrui ; Zhao, Qiuhua ; Chen, Yihua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c520t-2c01dd60f46c019bc9d295b2dbe868dab55e1505816dde67a5e42e7af08ea2f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Bioavailability</topic><topic>Chemistry</topic><topic>Monoclonal antibodies</topic><topic>New technology</topic><topic>Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pei, Haixiang</creatorcontrib><creatorcontrib>Peng, Yangrui</creatorcontrib><creatorcontrib>Zhao, Qiuhua</creatorcontrib><creatorcontrib>Chen, Yihua</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Engineered Materials Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Materials Research Database</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>RSC advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pei, Haixiang</au><au>Peng, Yangrui</au><au>Zhao, Qiuhua</au><au>Chen, Yihua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery</atitle><jtitle>RSC advances</jtitle><addtitle>RSC Adv</addtitle><date>2019-05-30</date><risdate>2019</risdate><volume>9</volume><issue>3</issue><spage>16967</spage><epage>16976</epage><pages>16967-16976</pages><issn>2046-2069</issn><eissn>2046-2069</eissn><abstract>Curing malignant carcinomas is a grand ambition in the development of human health. Over the past decades, targeted therapies have become one of the most successful ways of achieving this. Of these approaches, small molecule inhibitors and monoclonal antibodies are two major methods, however several barriers to their development and clinical use still exist. The use of proteolysis-targeting chimeras (PROTACs) is a new technology through utilizing a intracellular ubiquitin-proteasome system to induce targeted protein degradation, is receiving much attention in the field of targeted therapies. Hetero-bifunctional PROTACs have the potential to eliminate the "undruggable" proteome that comprises about 85% of human proteins, which indicates their great prospects in therapeutic fields. However, there are some hurdles preventing current PROTACs moving from bench to clinic, such as delivery and bioavailability. This review provides an overview of the development of PROTAC technology and will briefly summarize the future possible directions of this approach.
An overview of the latest developments in PROTAC technology and the possible directions of this approach is presented.</abstract><cop>England</cop><pub>Royal Society of Chemistry</pub><pmid>35519875</pmid><doi>10.1039/c9ra03423d</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-4031-447X</orcidid><orcidid>https://orcid.org/0000-0003-1733-7980</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2046-2069 |
ispartof | RSC advances, 2019-05, Vol.9 (3), p.16967-16976 |
issn | 2046-2069 2046-2069 |
language | eng |
recordid | cdi_crossref_primary_10_1039_C9RA03423D |
source | PubMed Central |
subjects | Bioavailability Chemistry Monoclonal antibodies New technology Proteins |
title | Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A49%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Small%20molecule%20PROTACs:%20an%20emerging%20technology%20for%20targeted%20therapy%20in%20drug%20discovery&rft.jtitle=RSC%20advances&rft.au=Pei,%20Haixiang&rft.date=2019-05-30&rft.volume=9&rft.issue=3&rft.spage=16967&rft.epage=16976&rft.pages=16967-16976&rft.issn=2046-2069&rft.eissn=2046-2069&rft_id=info:doi/10.1039/c9ra03423d&rft_dat=%3Cproquest_cross%3E2241344122%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c520t-2c01dd60f46c019bc9d295b2dbe868dab55e1505816dde67a5e42e7af08ea2f93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2241344122&rft_id=info:pmid/35519875&rfr_iscdi=true |